Trade

Aurobindo Pharma share price

Balanced risk
  • 27%Low risk
  • 27%Moderate risk
  • 27%Balanced risk
  • 27%High risk
  • 27%Extreme risk
  • 1,511.15(0.10%)
    May 15, 2026 15:29:52 PM IST
    • NSE
    • BSE
  • Vol : 735.27 K (NSE + BSE)
    Last 20 day avg : 1.34 M

Aurobindo Pharma is trading 0.10% upper at Rs 1,511.15 as compared to its last closing price. Aurobindo Pharma has been trading in the price range of 1,528.35 & 1,504.80. Aurobindo Pharma has given 27.72% in this year & 2.18% in the last 5 days. Aurobindo Pharma has TTM P/E ratio 19.70 as compared to the sector P/E of 24.31.There are 26 analysts who have initiated coverage on Aurobindo Pharma. There are 9 analysts who have given it a strong buy rating & 12 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 910.29 Crores in its last quarter.Listed peers of Aurobindo Pharma include Jagsonpal Pharmaceuticals (-0.22%), Themis Medicare (-0.50%), Neuland Laboratories (-1.38%).The Mutual Fund holding in Aurobindo Pharma was at 17.79% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Aurobindo Pharma was at 15.24% in 31 Mar 2026. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on May 16, 2026, 09:35 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.58
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.25
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.26
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    2.57
    Indicates overvaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
1,504.80
Highest
1,528.35
52 week range
Lowest
1,017.00
Highest
1,525.00
Aurobindo Pharma Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Jagsonpal Pharmaceuticals
Neutral
207.20-0.221,391.1233.885.541.253.18
Themis Medicare
Neutral
97.94-0.50902.0331.812.350.494.62
Neuland Laboratories
Bullish
16,471.40-1.3821,138.5092.9612.690.087.17
Pfizer
Moderately Bullish
4,847.103.4022,115.8836.125.460.691.60
Unichem Laboratories
Bearish
371.701.772,619.8523.181.29-3.51
Mutual Fund Ownership
View all
Quant Manufacturing Fund Regular Growth
NA
  • Amount Invested (Cr.) 71.15
  • % of AUM 8.19
Quant Mid Cap Fund Growth
3/5
  • Amount Invested (Cr.) 685.13
  • % of AUM 7.59
Mirae Asset Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 187.79
  • % of AUM 6.98
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 348.99
  • % of AUM 6.34
Quant Large and Mid Cap Fund Growth
4/5
  • Amount Invested (Cr.) 228.81
  • % of AUM 6.12
Aurobindo Pharma Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-21Audited Results
2026-04-06Buy Back of Shares
2026-02-09Quarterly Results
2025-11-05Quarterly Results
2025-08-04Quarterly Results & Interim Dividend
About the company Aurobindo Pharma
  • IndustryMajor Drugs
  • ISININE406A01037
  • BSE Code524804
  • NSE CodeAUROPHARMA
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its Key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. The Company is marketing its products globally in approximately 150 countries. The Company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltda, and others.
  • Management Info
  • Kambam ReddyExecutive Vice Chairman of the Board, Managing Director, Promoter
  • Santhanam SubramanianChief Financial Officer
  • B. Adi ReddyCompliance Officer, Company Secretary
  • Mettu Madan ReddyWhole-Time Director
Aurobindo Pharma Share Price FAQs

Aurobindo Pharma is trading at 1511.15 as on Fri May 15 2026 09:59:52. This is 0.10% upper as compared to its previous closing price of 1509.65.

The market capitalization of Aurobindo Pharma is 87767.84 Cr as on Fri May 15 2026 09:59:52.

The average broker rating on Aurobindo Pharma is Buy. The breakup of analyst rating is given below -

  • 9 analysts have given a strong buy rating
  • 12 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 3 analysts have given a sell rating
  • 1 analysts have given a strong sell rating

The 52 wk high for Aurobindo Pharma is 1525.00 whereas the 52 wk low is 1017.00

Aurobindo Pharma can be analyzed on the following key metrics -

  • TTM P/E: 19.70
  • Sector P/E: 24.31
  • Dividend Yield: 0.26%
  • D/E ratio: -

Aurobindo Pharma reported a net profit of 3485.89 Cr in 2025.

The Mutual Fund Shareholding was 17.79% at the end of 31 Mar 2026.